Evidence map›Paper›PMID 41241390›Full record

ArticleThe Journal of rheumatology2026

Association of Type III and Type VI Collagen Neoepitopes With Disease Severity in Systemic Sclerosis.

Ali Y Ayla, Elana J Bernstein, Meng Zhang, John M VanBuren, Flavia V Castelino, Lorinda Chung, Luke Evnin, Tracy M Frech, Jessica K Gordon, Faye N Hant and 21 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Ali Y AylaA.Y. Ayla, MD, M. Zhang, MS, M. Mayes, MD, MPH, Z.H. McMahan, MD, MS, B. Skaug, MD, PhD, S. Assassi, MD, MS, UTHealth Houston, Division of Rheumatology, Houston, Texas.ORCID 0000-0003-2581-7992
Elana J BernsteinE.J. Bernstein, MD, MSc, Y. Luo, MD, MHS, Division of Rheumatology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0001-5560-6390
Meng ZhangA.Y. Ayla, MD, M. Zhang, MS, M. Mayes, MD, MPH, Z.H. McMahan, MD, MS, B. Skaug, MD, PhD, S. Assassi, MD, MS, UTHealth Houston, Division of Rheumatology, Houston, Texas.
John M VanBurenJ.M. VanBuren, PhD, Division of Pediatric Critical Care, Department of Pediatrics, University of Utah, Salt Lake City, Utah.
Flavia V CastelinoF.V. Castelino, MD, Division of Rheumatology, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0001-9862-0299
Lorinda ChungL. Chung, MD, MS, Division of Immunology and Rheumatology, Stanford University and Palo Alto VA Health Care System, Palo Alto, California.
Luke EvninL. Evnin, PhD, Scleroderma Research Foundation, San Francisco, California.
Tracy M FrechT.M. Frech, MD, MS, Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, and Tennessee Valley Health Care System, Veterans Affair Medical Center, Nashville, Tennessee.ORCID 0000-0002-5472-3840
Jessica K GordonJ.K. Gordon, MD, MSc, K.S. Lakin, MD, MS, Division of Rheumatology, Hospital for Special Surgery, New York City, New York.
Faye N HantF.N. Hant DO, Division of Rheumatology, Medical University of South Carolina, Charleston, South Carolina.
Laura K HummersL.K. Hummers, MD, MSc, A.A. Shah, MD, MHS, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland.
Dinesh KhannaD. Khanna, MD, MS, C. Zahn, DO, University of Michigan Scleroderma Program, Division of Rheumatology, University of Michigan, Ann Arbor, Michigan.
Kimberly S LakinJ.K. Gordon, MD, MSc, K.S. Lakin, MD, MS, Division of Rheumatology, Hospital for Special Surgery, New York City, New York.ORCID 0000-0001-9343-5545
Dorota Lebiedz-OdrobinaD. Lebiedz-Odrobina, MD, RhMSUS, Division of Rheumatology, Department of Internal Medicine, University of Utah, Salt Lake City, Utah.
Yiming LuoE.J. Bernstein, MD, MSc, Y. Luo, MD, MHS, Division of Rheumatology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York.
Ashima MakolA. Makol, MD, Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Maureen MayesA.Y. Ayla, MD, M. Zhang, MS, M. Mayes, MD, MPH, Z.H. McMahan, MD, MS, B. Skaug, MD, PhD, S. Assassi, MD, MS, UTHealth Houston, Division of Rheumatology, Houston, Texas.
Zsuzsanna H McMahanA.Y. Ayla, MD, M. Zhang, MS, M. Mayes, MD, MPH, Z.H. McMahan, MD, MS, B. Skaug, MD, PhD, S. Assassi, MD, MS, UTHealth Houston, Division of Rheumatology, Houston, Texas.
Jerry A MolitorJ.A. Molitor, MD, PhD, Division of Rheumatic and Autoimmune Diseases, Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
Duncan F MooreD.F. Moore, MD, RhMSUS, C. Richardson, MD, MHS, Division of Rheumatology, Northwestern University, Chicago, Illinois.ORCID 0000-0001-9469-0919
Carrie RichardsonD.F. Moore, MD, RhMSUS, C. Richardson, MD, MHS, Division of Rheumatology, Northwestern University, Chicago, Illinois.
Nora SandorfiN. Sandorfi, MD, Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania.
Ami A ShahL.K. Hummers, MD, MSc, A.A. Shah, MD, MHS, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland.
Ankoor ShahA. Shah, MD, MHS, Division of Rheumatology and Immunology, Duke University, Durham, North Carolina.
Victoria K ShanmugamV.K. Shanmugam, MD, The George Washington University School of Medicine and Health Sciences, Department of Anatomy, George Washington University, Washington, DC.
Brian SkaugA.Y. Ayla, MD, M. Zhang, MS, M. Mayes, MD, MPH, Z.H. McMahan, MD, MS, B. Skaug, MD, PhD, S. Assassi, MD, MS, UTHealth Houston, Division of Rheumatology, Houston, Texas.
Virginia D SteenV.D. Steen, MD, Georgetown University Medical Center, Washington, DC.
Elizabeth R VolkmannE.R. Volkmann, MD, MS, Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California.
Carleigh ZahnD. Khanna, MD, MS, C. Zahn, DO, University of Michigan Scleroderma Program, Division of Rheumatology, University of Michigan, Ann Arbor, Michigan.
Wenjin J ZhengW.J. Zheng, PhD, UTHealth Houston, School of Biomedical Informatics, Houston, Texas, USA.
Shervin AssassiA.Y. Ayla, MD, M. Zhang, MS, M. Mayes, MD, MPH, Z.H. McMahan, MD, MS, B. Skaug, MD, PhD, S. Assassi, MD, MS, UTHealth Houston, Division of Rheumatology, Houston, Texas; Shervin.assassi@uth.tmc.edu.ORCID 0000-0002-8059-9978

Funding

Vasculopathy and Systemic Sclerosis-Associated Interstitial Lung DiseaseR01HL164758 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Elana J. Bernstein · 2022 to 2026
$3.5M
Interferon Regulatory Factor 7 Links Interferon Pathway Activation to the Exaggerates Fibrotic Response in Systemic SclerosisR01AR081280 · NIAMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Shervin Assassi, Minghua Wu · 2023 to 2026
$1.1M
Harnessing multivariate patient- and population-level disease trajectories to predict major clinical events in sclerodermaK24AR080217 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI Ami Aalok Shah · 2022 to 2026
$847k
Screening Chest CT to Detect Interstitial Lung Disease in Systemic SclerosisK23AR075112 · NIAMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BERNSTEIN, ELANA · 2019 to 2023
$794k
Combined Optical Coherence Elastography and Tomography for Assessing Skin Involvement in Systemic SclerosisR33AR078078 · NIAMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ASSASSI, SHERVIN, LARIN, KIRILL V · 2023 to 2023
$389k
NHLBI NIH HHS R01 HL164758NIAMS NIH HHS K23 AR075112NIAMS NIH HHS K24 AR080217NIAMS NIH HHS R01 AR081280NIAMS NIH HHS R33 AR078078
6 · The paper itself

Abstract

objectiveDysregulated collagen turnover is implicated in systemic sclerosis (SSc) pathogenesis. We evaluated collagen turnover biomarkers in relation to the severity of fibrotic manifestations, key cytokines, and progression in SSc.

methodsBaseline and 6-month serum samples of patients with early SSc in the Collaborative National Quality and Efficacy Registry (CONQUER) cohort were analyzed for type III (pro-collagen III [PRO-C3] and collagen III M [C3M]) and type VI (pro-collagen VI [PRO-C6] and collagen VI M [C6M]) collagen turnover biomarkers, as well as C-reactive protein (CRP), interleukin 6 (IL-6), and interferon (IFN)-inducible proteins. The modified Rodnan skin score and % predicted forced vital capacity (FVC%) served as surrogate markers of disease severity.

resultsA total of 222 patients were included. PRO-C3 (

conclusionPRO-C3 and PRO-C6 correlated with skin disease severity, whereas C3M and C6M correlated with lung disease severity. Collagen turnover biomarkers correlated with CRP, IL-6, and IFN-inducible proteins, providing support for the link between inflammation and fibrosis in SSc.

Indexed as

Collagen Type IIICollagen Type VIScleroderma, SystemicAdultAgedBiomarkersC-Reactive ProteinDisease ProgressionFemaleHumansInterleukin-6MaleMiddle AgedRegistriesSeverity of Illness IndexBiomarkersCollagen Type IIICollagen Type VIC-Reactive ProteinInterleukin-6biomarkercollagenfibrosissystemic sclerosis

Identifiers

PMID41241390
PMCPMC12638017

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.